Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$180.96 USD

180.96
830,357

+2.38 (1.33%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Charles River (CRL) Gains From Global Demand Amid FX Woes

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Charles River (CRL) Collaborates With Fondazione Telethon

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.

Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 2.28% and 1.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of 11.01% and 8.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) to Report Q2 Earnings: What's in Store?

Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.

Charles River's (CRL) Improved Volume Aids Amid Margin Woe

Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.

Charles River (CRL) Introduces LVV Packaging Plasmids

Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.

Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer

Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Charles River (CRL) to Build RightSource Lab With New Pact

Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.

Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) to Report Q1 Earnings: What's in Store?

Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.

Why Is Charles River (CRL) Down 14.8% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River's (CRL) New Cloud Platform Offers Real-Time Data

Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.

Charles River (CRL) Advances CDMO Portfolio With Latest Offer

Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.

Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes

The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.

Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip

Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.

Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.